Link to this page
Physician Data Query
| Preferred Name | enzalutamide | |
| Synonyms |
Xtandi ASP9785 MDV3100 benzamide, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-methyl- selective androgen receptor modulator MDV3100 |
|
| Definitions |
An orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Through a mechanism that is reported to be different from other approved AR antagonists, enzalutamide inhibits the activity of prostate cancer cell ARs, which may result in a reduction in prostate cancer cell proliferation and, correspondingly, a reduction in the serum prostate specific antigen (PSA) level. AR over-expression in prostate cancer represents a key mechanism associated with prostate cancer hormone resistance. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C71744" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C71744" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000560774 |
|
| altLabel |
Xtandi ASP9785 MDV3100 benzamide, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-methyl- selective androgen receptor modulator MDV3100
|
|
| cui |
C3496799 C3496793 C4721949 C2348174
|
|
| DATE FIRST PUBLISHED |
2007-07-24
|
|
| Date last modified |
2016-05-02
|
|
| definition |
An orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Through a mechanism that is reported to be different from other approved AR antagonists, enzalutamide inhibits the activity of prostate cancer cell ARs, which may result in a reduction in prostate cancer cell proliferation and, correspondingly, a reduction in the serum prostate specific antigen (PSA) level. AR over-expression in prostate cancer represents a key mechanism associated with prostate cancer hormone resistance. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C71744" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C71744" NCI Thesaurus)
|
|
| LT |
TRD
|
|
| NCI ID |
C71744
|
|
| notation |
CDR0000560774
|
|
| NSC Code |
766085
|
|
| ORIG STY |
Drug/agent
|
|
| prefLabel |
enzalutamide
|
|
| tui |
T109 T121
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |